Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Launch of Montelukast lR Tablets and Chewable
Transcript
@ ainntaphannnlimited T +9122 66061000 Mumbai400067 F +9122 66061200 E [email protected] lndia W www.ajantapharma.com Ajanta House, charkop, Kandivli west. 3'd December, 2015 Nationat Stock Exchange of India eii;nee ptaza, 5tF Ftoor, Ptot no. c/1, G Block Bandra-Kurta Complex, Bandra {East), BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Mumbai 400 051 Dear 5ir, Eq Scrip Code: BSE - AJANTPHAM 532331/ NSE AJANTPHARI Sub,: Launch of ,iontelukast lR Tablet! and Montelukast Chewable Tablets in t'S market Dear 5ir/Madam, USA to inform that our Company's subsidiary viz ' !"::". Pl*T: Tabtets in US market' We iaunlhet ti,tontetutast lR Tabtets and Montetuk"ast Chewabte enctoseherewithapressreleasebeingjssuedbythecomPanyjnthjsregard,foryour We are pteased Inc has information and records. Ptease acknowtedge the receiPt. Thankng You, Yours faithfuttY, FoT AJANTA PHARM LIMITED /:, -'4 l/t* GAURANG SHAH sr. G.M. - Legal & Compony seuetary Encl.: a/a Corborate ldentitv Number - t24230MH1979Ptd)22OS9 Press Release BSE: 532331 NSE: AJANTPHARM Reuters: AJPH.NS Bloomberg: AJP:IN Ajanta Pharma Announces the Launch of Montelukast IR Tablets and Montelukast Chewable Tablets Mumbai, India – (December 03rd, 2015) – Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg), generic versions of SINGULAIR® Tablets and SINGULAIR® Chewable Tablets, respectively. The United States Food & Drug Administration (US FDA) approval extends the breadth of the Montelukast offerings from Ajanta Pharma into three dosage forms (Immediate-Release Tablets, Chewable Tablets, and Oral Granules). Montelukast IR Tablets and Chewable Tablets are part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. To date, the US FDA has granted Ajanta Pharma five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA. About Ajanta Pharma Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology. For more details about www.ajantapharmausa.com. Ajanta Pharma USA Inc., please visit us at For Ajanta Pharma Ltd., you may visit us at www.ajantapharma.com. For specific queries, contact: Rajeev Agarwal Tel: +91 22 66061377 Email: [email protected] SINGULAIR® is a registered trademark of Merck & Co., Inc. Safe Harbour Statement CIN: L24230MH1979PLC022059 Registered Office: 98, Ajanta House, Charkop, Kandivili (West), Mumbai, 400 067, India. 1
